{"entity":{"id":"nct01639508","kind":"trial","name":"Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or A","aka":[],"tldr":"A phase 2 trial of cabozantinib in lung cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting.","summary":"Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity is a phase 2, interventional study registered as NCT01639508 by Memorial Sloan Kettering Cancer Center, with a registry enrolment figure of 86 participants, started 2012-07 and due to reach its primary completion in 2027-07. Interventions recorded: Cabozantinib. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: objective response rate (ORR) (Group A); objective response rate (ORR) (Group B). Lung eligibility wording from the registry: \"The subject has a pathologic diagnosis of non-small cell lung carcinoma that is metastatic or unresectable\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT01639508","url":"https://clinicaltrials.gov/study/NCT01639508"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["ros1-positive-nsclc","ret-fusion-nsclc","ntrk-fusion-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["cabozantinib"],"companies":["exelixis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01639508","phase":"2","setting":"A Phase II Study of Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity","sponsor":"Memorial Sloan Kettering Cancer Center","enrolled":86,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct01639508/","neighbours":{"cancer":[{"id":"ntrk-fusion-nsclc","kind":"cancer","name":"NTRK fusion-positive non-small-cell lung cancer","route":"/cancers/ntrk-fusion-nsclc/"},{"id":"ret-fusion-nsclc","kind":"cancer","name":"RET fusion-positive non-small-cell lung cancer","route":"/cancers/ret-fusion-nsclc/"},{"id":"ros1-positive-nsclc","kind":"cancer","name":"ROS1-positive non-small-cell lung cancer","route":"/cancers/ros1-positive-nsclc/"}],"drug":[{"id":"cabozantinib","kind":"drug","name":"Cabozantinib","route":"/drugs/cabozantinib/"}],"company":[{"id":"exelixis","kind":"company","name":"Exelixis","route":"/companies/exelixis/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}